Secor Capital Advisors’s Myriad Genetics MYGN Stock Holding History

Secor Capital Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-52,292	Closed	-$2.4M	–	559
2018 Q3	$2.4M	Buy	+52,292	New	+$2.33M	0.26%	116
2017 Q2	–	Sell	-100,425	Closed	-$1.93M	–	538
2017 Q1	$1.93M	Buy	100,425 +72,199	+256%	+$1.28M	0.21%	153
2016 Q4	$471K	Buy	+28,226	New	+$511K	0.06%	361
2016 Q3	–	Sell	-36,058	Closed	-$1.1M	–	616
2016 Q2	$1.1M	Buy	+36,058	New	+$1.25M	0.14%	226

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Secor Capital Advisors's MYGN Position: Q4 2018 in Review

Secor Capital Advisors sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 52,292 shares — an estimated $2.4M sold.

Secor Capital Advisors first reported a position in MYGN in Q2 2016 and held it in 4 quarters. The position peaked at $2.4M in Q3 2018. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

Secor Capital Advisors reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
Secor Capital Advisors sold 52,292 Myriad Genetics shares in Q4 2018, an estimated $2.4M.
Secor Capital Advisors first reported a position in Myriad Genetics in Q2 2016 and held it in 4 quarters.
Secor Capital Advisors's Myriad Genetics position peaked at $2.4M in Q3 2018.
264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on Secor Capital Advisors's 13F filing for Q4 2018, filed 14 Feb 2019.